阿帕替尼联合三线化疗治疗晚期非小细胞肺癌的临床疗效

目的:探讨阿帕替尼联合三线化疗治疗晚期非小细胞肺癌的临床疗效。方法:回顾性研究我院2015年06月至2017年06月给予阿帕替尼联合化疗治疗的晚期非小细胞肺癌患者22例,服用阿帕替尼联合化疗两周期后评估疗效和不良反应。结果:阿帕替尼联合化疗治疗晚期非小细胞肺癌,部分缓解率(PR)9.1%,疾病稳定率(SD)36.4%;常见的阿帕替尼相关不良反应发生率为乏力36.4%,高血压27.3%,口腔黏膜炎9.1%,且基本为1-2级不良反应。结论:阿帕替尼联合三线化疗治疗晚期非小细胞肺癌有一定的临床疗效,能够延长患者的生存时间,且耐受性良好。

Clinical efficacy of apatinib combined with third-line chemotherapy in the treatment of advanced non-small cell lung cancer

Objective:To investigate the clinical effect of apatinib combined with third-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).Methods:A retrospective study of 22 patients with advanced non-small cell lung cancer (NSCLC) treated with apatinib combined chemotherapy from June 2015 to June 2017 was conducted to evaluate the efficacy and adverse reactions after two cycles of apatinib combined chemotherapy.Results:In the treatment of advanced non-small cell lung cancer (NSCLC),the partial remission rate (PR) was 9.1%,and the disease stability rate was 36.4%.Apatinib related adverse reactions included:feeble (36.4%),hypertension (27.3%)，oral mucositis (9.1%),and basically 1-2 grade adverse reactions.Conclusion:Apatinib combined with third-line chemotherapy is effective in the treatment of advanced non-small cell lung cancer.It can prolong the survival time of the patients and has good tolerance.